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Background:  Comorbidity, such as diseases of the cardiovascular, pulmonary, and other systems may influence prognosis in lung cancer as well as complicate its treatment. The performance status of patients, which is a known prognostic marker, may also be influenced by comorbidity.  Due to the close link between tobacco smoking and lung cancer, and because lung cancer is often diagnosed in advanced ages (median age at diagnosis in Denmark is 70 years), comorbidity is present in a large proportion of lung cancer patients. 
Methods: Patients with any stage lung cancer who did not have surgical treatment were identified in the Danish Lung Cancer Registry (DLCR). DLCR collects data from clinical departments, the Danish Cancer Registry, Danish National Patient Registry (DNPR) and the Central Population Register. A total of 22,552 patients diagnosed with lung cancer in 2005-2011 were identified. Comorbidity data were extracted from the DNPR, which is a register of all in- and out-patient visits to hospitals in Denmark. By record linkage, lung cancer patients who had previously been diagnosed with comorbid conditions were assigned a Charlson comorbidity index (CCI).  Initial cancer treatment was categorized as chemotherapy, chemoradiation, radiotherapy or no therapy. Data on CCI, performance status, age, sex, stage, pulmonary function (FEV1), histology and type of initial treatment (if any) were included in univariable and multivariable Cox proportional hazard analyses.
Results: Treatment rates for chemotherapy and chemoradiation declined with increasing comorbidity and in particular increasing age. Women received treatment more often than men. In a univariable analysis of all patients combined, stage, performance status, age, sex, lung function and comorbidity were all associated with survival. Apart from excess mortality among patients with unspecified histological subtypes (HR), there was no clear difference between the specified subtypes. When adjusting for the other factors, particularly age, sex, performance status and stage proved to be robust while risk estimates for comorbidity were attenuated somewhat. When grouped by the three types of cancer treatment or no treatment, there was no influence of comorbidity on radiation therapy, and modest influence on survival after chemotherapy and chemoradiation. In contrast, age remained a strong negative prognosticator after multivariate adjustment as did stage and performance status. 




The simultaneous presence of cancer and other medical conditions (comorbidity) is frequent.  Cigarette smoking is the major risk factor for lung cancer (LC), and other tobacco related diseases are particularly frequently found in patients with LC (Janssen-Heijnen 2005). Comorbidity affects outcome in several ways such as reluctance towards diagnosis and therapy, and impaired tolerance to treatment (Bjerager 2006, Blanco 2008). Further, comorbidity may affect the performance status (PS) of the individual thereby reducing the efficacy and increasing the side effects of treatment. Anticancer treatment may worsen a number of common comorbid conditions such as diabetes and kidney failure, and comorbid diseases may directly shorten life expectancy. Comorbidity has been shown to be associated with suboptimal chemotherapy and with poor survival in clinical trials, and guidelines recommend that comorbidity be considered when planning treatment for patients with LC (Firat 2010, NCCN 2013). In general, outcome of therapy is dependent of multiple factors which in LC includes sex, stage, age and PS. However, the magnitude of the effect of comorbidity, and the interaction with PS and age is unknown, and we therefore conducted this study to determine the role of comorbidity on treatment rates and survival for patients with advanced (non-surgical) LC.

Methods:
Newly diagnosed patients with lung cancer were identified in the Danish Lung Cancer Registry for the period 2005-2011. The register covers all hospital departments in Denmark and collects information on diagnostic procedures, stage, ECOG performance status and first treatment (Jakobsen 2013). This information was supplemented by record linkage to the Central Population Register for information on survival, the National Pathology Register for pathology information and  to the National Patient Registry for information on previous illnesses (Andersen 1999, Lüchtenborg 2012).  The latter register contains coded discharge diagnosis and interventions related to diagnostic evaluation and treatment for all somatic patient admissions in Denmark. Information on comorbidity was included up to 10 year prior to LC diagnosis. Comorbidity was classified according to the scores from the weighted Charlson comorbidity index (CCI), however leaving out information on cancer related contact within 150 days before the date of LC diagnosis (Charlson 1987). If an individual had a disease coded more than once with a difference in severity (uncomplicated vs complicated or mild vs severe), the most severe score was used. The CCI is an extensively validated comorbidity measure and is calculated from 19 different disorders which can be grouped in 7 broader groups.
Patients were categorized in 4 age groups based on age at diagnosis.  Lung function was based on forced expiratory volume in 1 second (FEV1) as percent of predicted value and grouped in 4 groups. Clinical stage was based on clinical information on tumour, lymph nodes and metastasis and recoded according to the 7th edition of TNM. The non-surgical treatment was coded as no treatment, chemotherapy only, radiotherapy only or chemoradiation. Only the initial treatment was considered.
Multivariable logistic regression was used to calculate odds ratio (OR) and 95% confidence intervals (95%CI) for having chemo- or radiotherapy and chemoradiation according to comorbidity as well as age, sex, stage, histological subtype, FEV1 and PS. Univariable and multivariable Cox proportional hazard analysis were used to calculate hazard ratios (HR) and 95%CI for survival for the various categories.  χ2 tests were used to estimate the p-value for trend and heterogeneity,  excluding  missing value categories. 

Results
A total of 20,552 patients were identified, 4 had missing data on comorbidity and were excluded leaving 20,548 for the analysis. Slightly more men than women were included (53% vs 47%) and the median age at diagnosis was 69 years. For some variables there were missing data: lung function (FEV1) was missing for 35%, for cTNM 14% was missing and histological subtype was missing for 14% of patients (Table 1).
Of the 20,548, 10,270 (50%) had no comorbidity (CCI =0), 4,727 (23%) had a CCI of 1, 3,359 (16%) had a CCI of 2 and 2,192 (11%) had a CCI of 3 or more. Comorbid conditions and thus CCI appeared to increase with age although low CCI was found in the oldest age group of 80 years or older.  The majority of patients had advanced stage disease IIIa (14%), IIIB (13%) and IV (46%). Adenocarcinoma was the most frequent histology (26%) although the number of patients in unspecified categories of non-small cell lung cancer was high (31%). The most frequent type of initial treatment was radiotherapy (33%) followed by chemotherapy (17%) and chemoradiation (13%). No treatment was recorded as initial treatment for 7563 (37%) patients (Table I). Frequencies of the various comorbid conditions are shown in table 2. The most frequent comorbidity was chronic obstructive lung disease (COPD) found in 10% in lung cancer patients. Also a history of another cancer than lung cancer was observed in a substantial number (9%).  
Table 3 present’s odds ratios for having a specific treatment in relation to CCI, age and sex, and further adjusted for PS, FEV1, stage and histology. With increasing CCI the odds of having radio- and especially chemotherapy and chemoradiation was significantly reduced. For patients with a CCI of 3 or more, the odds ratios of having chemotherapy or chemoradiation were 0.54 and 0.61, respectively.  For patients above 70 years of age, the odds of having chemotherapy or chemoradiation was significantly reduced to such a degree that the odds ratios for having chemotherapy or chemoradiation for those age 80 years or more were 0.11 and 0.10 compared to patients younger than 60. A slight difference was found for sex with higher chemotherapy and chemoradiation treatment rates for women. In table 4 odds of receiving radiotherapy is shown by intent of treatment. CCI significantly affected the odds of having curative but not palliative radiotherapy
Survival was highly influenced by CCI with increasingly poor survival for patients with comorbidity (p for trend <0.001; Table 5). However, after multivariable adjustment the difference was attenuated so that the HR for CCI = 3 or more of 1.31 in the univariable analysis was reduced to a HR of 1.10 in the multivariable analysis. Likewise, a strong negative impact of age on survival was found although attenuated when controlled for other factors. Women had a significantly better survival than men (HRunivariable = 0.87), and this difference was actually more pronounced in the multivariable model (HRmultivariable= 0.81). Performance status was strongly associated with survival (p for trend <0.001) so that patients with a PS of 4 had a HRunivariable of 6.54 which was somewhat reduced when adjusted for other factors (HRmultivariable = 4.31). Some histological subtypes were found to be associated with higher death rates: compared to adenocarcinoma, non-small cell lung cancer (NSCLC), large cell, and not otherwise specified and unknown subtype LC with HRunivariable  of 1.27, 1.19 and 1.36, respectively. These estimates were attenuated, but remained significant after adjustment for other factors. Finally, as expected, stage was a very strong and robust indicator for survival. HRunivariable for survival increased gradually up to 4.09 for stage 4, ptrend<0.0001. The estimates remained virtually unchanged after adjustment.
Table 6 examines HR for survival for the 3 treatment categories by CCI and the other main prognostic factors: age, sex, PS and stage. For patients with radiotherapy as initial treatment, there was actually a trend towards better survival for increasing comorbidity (ptrend = 0.09) and higher age (ptrend = 0.003). Again a significantly better survival was seen in women. Conversely, a worse survival was seen with poor PS and higher stages. While stage remained very robust after adjustment, somewhat attenuated HR’s were seen when PS was adjusted.  For chemotherapy there was a clear trend for poor prognosis being associated with high degree of comorbidity, age, PS and stage (ptrend=<0.001 for all variables).  As previously,women had better survival than men. For chemoradiation a modest effect of comorbidity (ptrend=0.44) and age (ptrend =0.02) was found. Advanced PS and stage was highly strongly associated with poor survival with HRunivariable for PS=4 and stage= IV of 2.49 and 2.54 respectively.

Discussion
The CCI appeared to increase with age although low CCI was found in the oldest age group of 80 years or older. This could indicate some degree of nihilism among patients or health professionals regarding diagnostic work-up among the very old leaving the fit elderly for diagnostic work-up. With increasing CCI a decrease in odds of having chemotherapy and chemoradiation was found, and but for radiotherapy, this association was only seen for treatment with curative intent.
CCI was a modest prognostic factor for survival of LC and risk estimates for comorbidity were attenuated when controlled for other factors such as PS and stage. Conversely, stage, sex and PS were strong prognostic factors, and were robust to adjustment. This indicates that it is the performance status at diagnosis rather than the history of comorbid conditions that affects the outcome for LC patients. The data used in this study are of high quality. There is no private sector for cancer diagnosis or treatment in Denmark, and health care is provided for free including cancer medication. Therefore, all patients are in public disease registers. Records held by The Danish Lung Cancer Registry are cross checked with other disease register such as the Cancer Registry, and are estimated to be virtually complete (Jakobsen 2013). The central population register includes the total Danish population and is updated daily. All pathology data are kept at the Pathology Register. The information on comorbidity that we have used is derived from the National Patient Register which keeps records for all contacts (in- or outpatient) to Danish hospitals. For each contact, information on primary and secondary diagnosis and date are recorded (Andersen 1999). Linkage between registers is carried out using a unique personal identifier and there is thus no loss to follow-up. In order to ascertain the presence of comorbid conditions, we retrieved all information on relevant diagnosis to construct the CCI. Although CCI includes grading for some conditions, more exact information regarding severity of most or treatment for comorbid conditions was not available. A record, of, say diabetes mellitus with complications, thus indicates the presence of this condition but not whether this condition actually influenced the patient’s performance or ability to tolerate treatment. As this represent non-differential misclassification, the true effect of comorbidity may actually be larger than what we have found. We analysed CCI as an indicator of comorbidity but not the individual diseases that are included in the CCI. 
Throughout the analysis, PS was a stronger and more robust risk factor than CCI. It is however likely that these two factors are closely linked as comorbidity may lead to decreased PS. The adjustment of one for the other in a multivariate analysis may indicate which factor is most important but the effects cannot be completely separated. An important aspect of this part of the analysis is that CCI was based on medical history while PS was determined at the time of diagnosis by the pulmonologist. 
Our finding that low lung function was associated with a poorer survival corroborates observations from other studies (Lopez-Encuentra 2005). A normal lung function is usually required for curative chemo-radiation. For palliative treatment, a reduced lung function would render the patient more susceptible to complications such as pneumonia. Also, a poor lung function would in many cases have a negative impact on PS. Not all comorbid conditions are equally harmful. Diabetes may provide the exception as this comorbid condition may actually improve prognosis although data is conflicting (Hatlen 2011, Shieh 2012). It has been suggested that CCI may not be the best measure of comorbidity because it does not necessarily capture the relevant comorbidities (Tammemagi 2003). Some co-morbidities’ that may be important for choice of systemic treatment in LC such as polyneuropathy and benign hematologic conditions are not part of the score basis for CCI. 
Factors such as stage, PS, patient preferences and co-morbidity are considered when a treatment plan is made for an individual patient. It is therefore not surprising that the rates of treatments that are difficult to tolerate such as chemotherapy and in particular chemoradiation are lower in the more co-morbid patients. We found that treatment was given less frequently to older age groups, perhaps because it is known that risk of side effects are greater in the older LC population. The odds that women receive chemotherapy and chemoradiation are higher than in men. This may partially explain the survival benefit uniformly found in women. Our findings regarding treatment rates of non-surgical treatment modalities are in line with previous studies. Lower treatment rates were found among older and more comorbid patients in 2 US studies. Age appeared to be a stronger negative factor for usage than comorbidity, and, as in our study, usage of chemotherapy in the oldest age category was very limited (Wang 2012, Ritzwoller 2012).  
Comorbidity as a prognostic factor has been examined in several previous publications. A Danish study based on 1702 LC patients concluded that both overall and cancer specific mortality was increased in patients with CCI ≥ 3 (HR was 1.51 and 1.29 respectively) (Jørgensen 2012). Another study found increased mortality for subgroups of patients with comorbidity, and also found that the general increase in survival rates were less pronounced for patients with a high CCI (Deleuran 2013).
As comorbidity is a prognostic factor, we need to ascertain this for risk stratification of patients who are candidates for treatment for LC. For surgical patients, a multivariable risk score system has been developed (Thoracoscore), with nine variables which may be a useful clinical tool for predicting risk of death (Falcoz 2007). Thoracoscore has been incorporated in the British Thoracic Society guidelines to evaluate the operative mortality risk of patients undergoing thoracic surgery (Lim 2010). No similar instrument has been developed for non-surgical LC patients. 
An interesting feature about comorbidity is that we may have some influence over it in contrast to sex and age. If comorbidity was well controlled in LC patients, an improvement in PS and ability to tolerate treatment could be anticipated. Significant excess non-cancer mortality has been found in long term LC survivors, and most likely this is caused by comorbidities (Janssen-Heijnen 2012).  A study of comorbidity care found inconsistent differences between cancer survivors and matched controls, some patients (colorectal) received less comorbidity care while other  (breast and prostate) received equivalent or more care than controls (Snyder 2013). It is likely that care for comorbid conditions is better for patients with a generally good prognosis than for those with a poor prognosis. To address this problem, incorporation of comorbidity clinics in the oncology wards, perhaps in conjunction with other measures directed at improving PS such as physical exercise and dietary instruction, could potentially improve survival.
We have no information as to the exact anticancer drug use on an individual basis. It is possible that treatments with a low grade of toxicities such as tyrosine kinase inhibitors may be used more extensively among older or more comorbid patients than chemotherapy.
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Table 1. Prognostic factors by Charlson comorbidity score
			Charlson comorbidity score
 	Total	0	1	2	3+



































































Moderate or severe kidney disease	293	29	10%	80	27%	110	38%	74	25%












Table 3. Odds ratio for receiving cancer treatment by comorbidity score, age and sex	
	     Radiotherapy	Chemotherapy	Chemoradiation	

















Multivariable models are adjusted for variables shown, as well as ECOG performance status, lung function (FEV1 %predicted), stage and histological type	
CI: confidence interval	
χ2 for trend or heterogeneity, where appropriate	
										











Multivariable logistic regression models are adjusted for age, sex, ECOG performance status, lung function (FEV1 %predicted), stage and histological type
OR: odds ratio
CI: confidence interval
χ2 for trend or heterogeneity, where appropriate





















































Table 6. Survival among non-resected lung cancer patients stratified by treatment
	Radiotherapy	Chemotherapy	Chemoradiation
	Univariable	Multivariable	Univariable	Multivariable	Univariable	Multivariable



































CI: confidence interval, χ2 for trend or heterogeniety, where appropriate, Survival time is calculated from start of treatment
																		








